Nykode Therapeutics ASVACBF 28 Dividend Yield % is 30.64% as of Jun. 25, 2026, which is 23% below its 10-year median of 39.90. GuruFocus rates VACBF with a GF Score™ of 28/100 and a GF Value™ of $0.76 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 151 Biotechnology companies, Nykode Therapeutics AS ranks better than 99.34% on this metric.
As of today (2026-06-25), the Trailing Annual Dividend Yield of Nykode Therapeutics AS is 30.64%.
The historical rank and industry rank for Nykode Therapeutics AS's Dividend Yield % or its related term are showing as below:
VACBF'
s Dividend Yield % Range Over the Past 10 Years
Min: 26.03 Med: 39.9 Max: 67.03
Current: 30.64
During the past 9 years, the highest Dividend Yield of Nykode Therapeutics AS was 67.03%. The lowest was 26.03%. And the median was 39.90%.
VACBF's Dividend Yield % is ranked better than 99.34% of 151
companies
in the Biotechnology industry
Industry Median: 1.5
vs VACBF: 30.64
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Nykode Therapeutics AS (OTCPK:VACBF) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Nykode Therapeutics AS Dividend Yield % Related Terms
Nykode Therapeutics AS Dividend Yield % Historical Data
* Premium members only.
The historical data trend for Nykode Therapeutics AS's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VACBF vs VRTX, REGN, ALNY: Dividend Yield % Comparison
For the Biotechnology subindustry, Nykode Therapeutics AS's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nykode Therapeutics AS Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nykode Therapeutics AS's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Nykode Therapeutics AS's Dividend Yield % falls into.
Nykode Therapeutics AS (VACBF) has a Dividend Yield % of 30.64% as of Jun. 25, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Nykode Therapeutics AS and its competitors. This is 23% below median its historical median of 39.90. Over the past decade, Nykode Therapeutics AS's Dividend Yield % has ranged from 26.03 to 67.03. According to the industry distribution chart, Nykode Therapeutics AS ranks #1 out of 151 companies in the Biotechnology industry, placing it in the top 0.7%.
Is Nykode Therapeutics AS's Dividend Yield % too high?
Nykode Therapeutics AS's current Dividend Yield % of 30.64% is 23% below median its 10-year median of 39.90. Over the past 10 years, this metric has ranged from a low of 26.03 to a high of 67.03. The Biotechnology industry median Dividend Yield % is 1.50. Nykode Therapeutics AS's value of 30.64% is 1942.7% above this industry median. Based on the distribution chart, Nykode Therapeutics AS ranks #1 out of 151 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Nykode Therapeutics AS has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nykode Therapeutics AS ranks #1 out of 151 companies for Dividend Yield %. This places Nykode Therapeutics AS in the top 1% of its industry — outperforming the majority of peers. The industry median Dividend Yield % is 1.50. Nykode Therapeutics AS's value of 30.64% is 1942.7% above this benchmark. Historically, Nykode Therapeutics AS's own Dividend Yield % has ranged from 26.03 to 67.03 over the past decade. While the company's 10-year median is 39.90 vs. the industry median of 1.50, Nykode Therapeutics AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.50, based on 151 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nykode Therapeutics AS's current Dividend Yield % of 30.64% is 1942.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Nykode Therapeutics AS and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nykode Therapeutics AS's current Dividend Yield % is 30.64%, which is 23% below median its own 10-year median of 39.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (VACBF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.76, compared to a current price of $0.32 — trading 57.3% below its estimated fair value. The current Dividend Yield % is 30.64%, which is 23% below median its 10-year median of 39.90 and 1942.7% above the Biotechnology industry median of 1.50. Nykode Therapeutics AS's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Nykode Therapeutics AS (VACBF), the current Dividend Yield % is 30.64% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nykode Therapeutics AS (VACBF) Overvalued in 2026?
Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued.
The current stock price of $0.32 is trading 57.3% below its estimated GF Value™ of $0.76.
GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.
Key valuation signals for VACBF:
Dividend Yield %: 30.64% (23% below median its 10-year median of 39.90)
GF Value™: $0.76 vs. price of $0.32 (57.3% below fair value)
Industry Position: 1942.7% above the Biotechnology median (#1 of 151)
No single metric tells the full story. See the VACBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
28GF Score
Get the complete analysis for VACBF
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VACBF has been successfully added to your 
